Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG INNOLET versus NOVOLOG MIX 70 30 PENFILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG INNOLET versus NOVOLOG MIX 70 30 PENFILL.
NOVOLOG INNOLET vs NOVOLOG MIX 70/30 PENFILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase activity, which leads to glucose transporter translocation and metabolic effects.
Novolog Mix 70/30 is a biphasic insulin analog suspension containing 70% insulin aspart protamine (intermediate-acting) and 30% insulin aspart (rapid-acting). Insulin aspart binds to the insulin receptor (IR) on target cells (muscle, adipose, liver), activating tyrosine kinase signaling, which promotes glucose uptake via GLUT4 translocation, inhibits hepatic gluconeogenesis, and stimulates glycogen synthesis and lipogenesis.
Subcutaneous injection, 0.5-1.0 unit/kg/day in divided doses, with meals.
Subcutaneous injection, typically 0.5–1 unit/kg/day divided into two doses: two-thirds in the morning and one-third in the evening, adjusted based on blood glucose levels.
None Documented
None Documented
Terminal half-life: 81 minutes (range 70–90 minutes) for subcutaneous administration; reflects absorption-rate limited elimination
Biphasic: first phase (distribution) 0.5-1 h; terminal (elimination) 5-7 h (insulin aspart component). Clinical context: covers prandial and basal needs with twice-daily dosing.
Renal: approximately 30% of total clearance as unchanged drug; hepatobiliary/fecal: minor (less than 1%)
Renal: 100% (protamine and insulin are metabolized and excreted via kidneys; no unchanged drug excreted in urine). Biliary/fecal: negligible.
Category C
Category C
Insulin Analog
Insulin Analog